Atara Biotherapeutics, a company based in Thousand Oaks, is navigating a precarious situation after the FDA rejected its lead drug candidate, Ebvallo, for the second time in less than a year. This unexpected decision has left executives and investors grappling with the implications for the company’s future.
On January 12, Atara announced the FDA’s rejection, leading to a staggering 57% plunge in its stock price on that trading day alone. The downturn continued the following day, further erasing over two-thirds of the company’s market capitalization. The sudden nature of the FDA’s decision took Atara’s leadership by surprise, as expressed by CEO Cokey Nguyen, who described the experience as “completely blindsiding.”
Drug Background and Market Potential
Ebvallo, or tabelecleucel, is designed to treat a rare but severe condition involving malignant immune cells triggered by the Epstein-Barr virus in patients who have undergone organ or tissue transplants. In the absence of treatment, these malignant cells can lead to a challenging and often fatal form of lymphoma. Despite the rarity of post-transplant lymphoma, Atara estimates the U.S. market potential for Ebvallo to exceed $500 million.
The drug was developed in collaboration with Pierre Fabre Laboratories, a major player in the pharmaceutical industry. While the European Commission approved Ebvallo for sale across EU member countries in late 2022, its pathway in the U.S. has been fraught with challenges.
Regulatory Obstacles: Previous and Current Challenges
The FDA’s initial rejection in January 2022 stemmed from concerns regarding deficiencies in the drug’s manufacturing process. Following this, Atara and Pierre Fabre engaged with the FDA to devise a corrective plan and resubmitted their application in August, anticipating approval.
However, instead of a favorable response, the FDA issued a “complete response letter,” indicating that the clinical trial structure was insufficient for demonstrating the drug’s effectiveness for accelerated approval. Nguyen noted this was the first time the FDA raised concerns about the adequacy of the clinical trial design.
Clinical Trial Design and FDA Expectations
The FDA’s recent rejection highlighted the necessity for a “double-arm” clinical trial, which contrasts with the single-arm design utilized by Atara and Pierre Fabre. A double-arm trial compares a drug’s efficacy against a placebo or established treatment, while a single-arm trial can expedite processes in cases of rare diseases. Nguyen emphasized that a single-arm approach was ethically justified for patients facing life-threatening conditions.
This shift in regulatory expectations raises concerns for the bioscience industry, as tougher scrutiny can significantly impact companies that have invested substantial resources into clinical trials. As noted by industry experts, the percentage of drugs making it through to FDA approval has been declining, and changing criteria can leave companies vulnerable.
Next Steps for Atara Biotherapeutics
In response to the FDA’s feedback, Pierre Fabre is planning to request a “Type A” meeting with the FDA to discuss their concerns and explore potential pathways to approval. This meeting is crucial for both companies, especially for Atara, which has faced severe workforce reductions, dwindling from 440 employees to just 14 in recent months.
Atara’s financial situation has also worsened, with only $8.5 million in cash and short-term investments remaining. The anticipated $31 million milestone payment from Pierre Fabre is now delayed, and its future hinges on the outcome of discussions with the FDA.
Viability and Future Options
Nguyen remains hopeful that the meeting will clarify a route to approval, citing the drug’s established use in Europe as a positive factor. However, the stakes are high, and if the FDA meeting does not yield a clear path forward, Atara may face severe consequences.
Industry analysts suggest that, despite the European approval, addressing Atara’s immediate cash flow crisis poses a significant challenge. If the FDA meeting does not provide clarity, Atara may have to consider drastic measures for survival, including potential mergers or alternative financing avenues.
Conclusion
Atara Biotherapeutics stands at a critical crossroads, with its future resting on the impending dialogue with the FDA. The company’s journey underscores the complexities of drug development in the bioscience field, particularly in navigating regulatory environments. As Atara seeks a lifeline, the outcome of this situation will be pivotal not only for the company but also for the broader landscape of rare disease treatment.
Key Takeaways:
- Atara Biotherapeutics faced a second FDA rejection for Ebvallo, leading to a severe stock price decline.
- The company is grappling with financial constraints and a significant reduction in workforce.
-
The FDA’s evolving expectations for clinical trial designs reflect increasing scrutiny in drug approvals.
-
Atara’s future hinges on an upcoming meeting with the FDA to discuss potential pathways to approval.
-
The company may need to explore alternative strategies for survival if the meeting does not yield favorable outcomes.
Read more → labusinessjournal.com